The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity ...
Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and ...
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which ...
"Understanding biologic therapy trajectories in Medicaid is important, given its distinct formulary restrictions and patient demographics," they concluded. "Interventions must not only address access ...
With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...
Feb 18 (Reuters) - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b ...
Researchers identified multiple gene signatures linked to psoriasis severity, body weight, and immune activity. These ...
New findings indicate that in adults with moderate-to-severe plaque psoriasis who are overweight or obese, combined treatment with ixekizumab (Taltz) and tirzepatide (Zepbound) results ...
AJMC: Please describe the process for the treatment of psoriasis currently at your health system, Emory Healthcare. What guidelines/pathways are involved? HAUMSCHILD: Our psoriasis treatment approach ...
When you have psoriasis — a skin disease that typically causes thick, itchy, scaly, or discolored patches of skin — finding a treatment that works for you can be a challenge. Luckily, there are more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results